Earnings Call · Q4 FY2022·2022-09-23

Q4 22EPS -100.00%*·Rev n/aQ3 22EPS -1.35%·Rev n/aQ2 22EPS -32.07%·Rev n/aQ1 22EPS +29.96%·Rev n/a⚠ consensus missing

InMed Pharmaceuticals Inc. INM

Colin Clancy — Vice President of Investor Relations

Eric Adams — Chief Executive Officer (CEO)

Michael Woudenberg — Executive (likely in commercial operations or product development)

Brenda Edwards — Chief Financial Officer (CFO)

−8.3%1d on move date−7.3% vs SPY3d+4.5%5d+18.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INM calls or request research access.

More INM calls Browse calls Request research access